Hints and tips:
Related Special Reports
...It has also worked on drug development for US pharma company Johnson & Johnson, Danish biotech group Genmab and British biotech Iksuda therapeutics....
...The Development Bank of Japan said it wanted to connect the country’s start-ups with others across the world....
...Johnson’s team has said he was acting as a diplomatic back channel for the UK with the “active support” of the Foreign, Commonwealth and Development Office....
...David Moore, vice-president for corporate development, added that the company would focus on acquisitions in diabetes and obesity, ideally in the early stage of development....
...In March Johnson’s team said of his visit to Venezuela that he was acting as a diplomatic back channel for the UK with the “active support” of the Foreign, Commonwealth and Development Office....
...Lab monkey prices in China have plummeted as a post-pandemic slowdown in drug development ripples through the pharmaceutical sector in the world’s second-largest economy....
...[Enlarge] Further reading:— Alert: Alphaville LLC issues new research report on Duchy of Cornwall (FTAV)— Greenland: Alphaville put on its sellside hat for the deal of the century (FTAV)— Alphaville LLC...
...Johnson’s team have said he had acted as a “diplomatic back channel for the UK”, but the Foreign, Commonwealth and Development Office said he was “not acting on behalf of the UK government”....
...Developing new antibiotics is often unattractive for pharmaceutical companies, as research and development costs are high but their use is designed to be limited to reduce the risk of the product driving...
...Susan Galbraith, executive vice-president of oncology research and development at AstraZeneca, said there was an “opportunity to improve” on existing drugs in the area and that the Fusion acquisition would...
...It has pledged to double funding for dementia research to £160mn a year by 2025....
...Since the third quarter of 2023 when it had 82 new drugs in development, the company has jettisoned 16 drugs and added 12 others, including the weight-loss drug it gained through its $3.1bn acquisition of...
...Jodie Keane Senior Research Fellow ODI (Formerly Overseas Development Institute), London SE1, UK...
...He sold off assets in non-core areas to invest heavily in research and development, plus fund acquisitions. There were setbacks, including criticism over its accounting practices....
...Novo Nordisk purchased Dicerna Pharmaceuticals, a company focused in RNA-based therapeutics, for $3.3bn in 2021....
...The results will renew attention on the possible effectiveness of lixisenatide, which is made by French pharmaceutical group Sanofi, and other so-called GLP-1 drugs against neurodegenerative conditions....
...One of his most well-known contributions to research is the ‘Sally-Anne task’....
...Spravato, a nasal spray based on a molecule from the psychedelic drug ketamine used to treat depression, already ranks as Johnson & Johnson’s fastest-growing product....
...In 2022/23, NIHR research expenditure for all cancers was £121.8mn.”...
...Over the past year or so, the rapid development of artificial intelligence has sparked trepidation over how it may disrupt various facets of the modern world — from job security to the development of new...
...In October, pharmaceuticals companies Eisai and Eli Lilly unveiled research showing the benefits of using new Alzheimer’s drugs very early in the development of the disease....
...High demand for weight-loss drugs has helped Novo Nordisk become Europe’s largest company by market capitalisation, while Eli Lilly overtook Johnson & Johnson as the world’s largest pharmaceutical company...
...“But the elegant synthetic design of cresomycin, based on an intuitive rationale, provides an exciting scaffold for further development.”...
...Pharmaceuticals companies are using AI to identify new molecules as targets for possible anticancer drugs....
...IDA’s Lohan warned of erecting new “barriers within the research and development cycle of new treatments” and possibly delaying market access....
International Edition